Trekrezan for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Trekrezan, a synthetic compound sold in Russia as an over-the-counter medicine to raise general resistance to infection, cold, low oxygen and heavy workloads, has never been studied for aging or lifespan. Two small human studies suggest respiratory infections resolve somewhat faster and physical performance holds up better in the cold. Short courses appear well tolerated; the main open safety question is long-term exposure to one of its two components. (Full Review)

Protocol

Standard prevention course
200 mg once daily for 14 days
After meals; adults and children over 12
Acute infection or high-workload course
600 mg on day one, then 200 mg daily for 7 days
Day-one dose split into three 200 mg doses
Pre-exposure single dose
0.2 g before cold exposure
Regimen tested in healthy young men before 40 minutes at −10 °C
Time to effect
Acute respiratory viral infections
By day 3
Temperature normalized in more treated than untreated patients; symptoms resolved 2.2 days sooner (open study without placebo)
Physical work capacity under cold stress
Single dose before exposure
Performance held at comfortable-temperature levels; cold lowered it without the drug
Neurotic disorders, alongside tranquilizers
Day 3–5
Effects increasing through the second week at 0.3 g daily (secondary review)

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Children under 12 years
  • Hereditary lactose intolerance, lactase deficiency, or glucose-galactose malabsorption
  • Known hypersensitivity to any component
  • Active autoimmune disease or organ-transplant immunosuppression (inferred; no human data)
Key Interactions
Theoretical (inferred from mechanism)
  • Immunosuppressants (e.g., cyclosporine, tacrolimus): possible weaker disease or rejection control
  • Interferons and interferon inducers (e.g., peginterferon alfa, tilorone): possible flu-like symptoms or excessive immune activation
  • Drugs cleared by glucuronidation (acetaminophen/paracetamol, valproate): possible higher or lower levels of the other drug
  • Adaptogen and immune-stimulating supplements (Eleutherococcus senticosus, Rhodiola rosea): unknown cumulative stimulation, including sleep disruption
  • Vaccination: possible altered vaccine response, direction untested in humans

Risk & Side Effects

  • Low: Allergic and hypersensitivity reactions
  • Speculative: Tumors from the triethanolamine component; kidney strain at high exposure; immune overactivation in autoimmune disease

Monitoring

Marker Target Why
White blood cell count with lymphocyte count 4.5–11.0 ×10⁹/L total; lymphocytes 1.0–4.8 ×10⁹/L Immune modulation
ESR (erythrocyte sedimentation rate) 0–20 mm/h Inflammation marker
Fasting plasma glucose 70–99 mg/dL Safety check: label caution in diabetes
Serum creatinine 0.7–1.3 mg/dL men; 0.6–1.1 mg/dL women Safety check: renal excretion
eGFR (estimated glomerular filtration rate) Not specified in the ER Kidney filtration, paired with creatinine

Cadence: Baseline before a first course; repeat blood count at the end of each 8–14-day course if baseline values were abnormal; daily home glucose during each course for people with diabetes; creatinine every 6–12 months if courses are repeated several times a year

Qualitative Assessment

  • Number and duration of respiratory infections per season, compared with the individual's own previous seasons
  • Fatigue and energy during heavy physical or mental workloads
  • Tolerance of cold, heat or altitude exposure
  • Sleep quality during courses
  • Any skin rash, itching or swelling, as an allergy warning sign